Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers

Exclusion Criteria

• •History of any clinically significant disease or malignancy excluding non-melanoma skin cancer
• •History of liver disease, liver dysfunction, liver enzyme elevations, or Gilbert's disease
• •History of acute or chronic pancreatitis or pancreatic insufficiency
• •History of gout, hyperuricemia, or crystalluria
• •History of chronic pain requiring medical therapy
• •Positive test for hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg)
• •Positive test for human immunodeficiency virus (HIV) antibody
• •Clinical laboratory tests outside the normal limits and considered by the investigator to be clinically significant
• •The subject has difficulty swallowing tablets
• •Clinically significant illness within one month prior to study drug administration
• •History of drug or alcohol abuse within 2 years prior to study drug administration
• •Treatment with prescription medication (with the exception of contraceptives and hormone replacement therapy (HRT)) or complementary and alternative medicines (CAM) within 14 days; over-the-counter products with exception of ibuprofen within 14 days; or alcohol, grapefruit or grapefruit juice containing beverage within 72 hours
• •Donated blood or has had significant blood loss within 56 days prior to study drug administration or has donated plasma within 7 days prior to study drug administration